FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gerrit Jan Weverling

Research Profile

Living Beings

HIV-1

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Geographic Areas

Netherlands

Co-author Network

Publications

TOP 3
Susanna Esposito; Valentina Fabiano; Paola Marchisio; Valentina Montinaro; Elena Pariani; Valentina Pivetti; Gerrit Jan Weverling; Alessandro Zanetti; Antonella Amendola; Sonia Bianchini; Gian Vincenzo Zuccotti
The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.
Stefan Kostense; Wilfred Marissen; Susan Moore; Rie von Eyben; Gerrit Jan Weverling; Alexander B H Bakker; Arjen Companjen; Cathleen Hanlon; Jaap Goudsmit
Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.
Roland Zahn; Jerome H H V Custers; Gert Gillisen; Jaap Goudsmit; Maria Grazia Pau; Marina Koning; Katarina Radošević; Anna Roos; Hanneke Schuitemaker; Dirk Spek; Esmeralda van der Helm; Jort Vellinga; Mo Weijtens; Gerrit Jan Weverling; Ariane Rodríguez
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gerrit Jan Weverling (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Susanna Esposito; Valentina Fabiano; Paola Marchisio; Valentina Montinaro; Elena Pariani; Valentina Pivetti; Gerrit Jan Weverling; Alessandro Zanetti; Antonella Amendola; Sonia Bianchini; Gian Vincenzo Zuccotti
The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.
Vaccine 2012;30(49):7005-12.
2012: Stefan Kostense; Wilfred Marissen; Susan Moore; Rie von Eyben; Gerrit Jan Weverling; Alexander B H Bakker; Arjen Companjen; Cathleen Hanlon; Jaap Goudsmit
Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples.
Antimicrobial agents and chemotherapy 2012;56(7):3524-30.
2012: Roland Zahn; Jerome H H V Custers; Gert Gillisen; Jaap Goudsmit; Maria Grazia Pau; Marina Koning; Katarina Radošević; Anna Roos; Hanneke Schuitemaker; Dirk Spek; Esmeralda van der Helm; Jort Vellinga; Mo Weijtens; Gerrit Jan Weverling; Ariane Rodríguez
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.
PloS one 2012;7(12):e44115.
2011: Rebecca Jane Cox; Katja Hoschler; Jaco Klap; Ronald Kompier; Abdullah Sami Madhun; Kenneth C McCullough; Jane Kristin Nøstbakken; Gabriel Pedersen; Marianne Sævik; Signe Svindland; Gerrit Jan Weverling; Marieke Willemsen; Maria Zambon; Lucy Breakwell; Laura Campitelli; Haakon Sjursen
Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
Vaccine 2011;29(45):8049-59.
2010: Brian Abel; Michele Tameris; Nazma Mansoor; Sebastian Gelderbloem; Jane Hughes; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Marwou de Kock; Linda van der Merwe; Anthony Hawkridge; Ashley Veldsman; Mark Hatherill; Giulia Schirru; Maria Grazia Pau; Jenny Hendriks; Gerrit Jan Weverling; Jaap Goudsmit; Donata Sizemore; J Bruce McClain; Margaret Goetz; Jacqueline Gearhart; Hassan Mahomed; Gregory D Hussey; Jerald C Sadoff; Willem A Hanekom
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
American journal of respiratory and critical care medicine 2010;181(12):1407-17.
2010: Robert H E Friesen; Wouter Koudstaal; Martin H Koldijk; Gerrit Jan Weverling; Just P J Brakenhoff; Peter J Lenting; Koert J Stittelaar; Albert D M E Osterhaus; Ronald Kompier; Jaap Goudsmit
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
PloS one 2010;5(2):e9106.
2009: Wouter Koudstaal; Martin H Koldijk; Just P J Brakenhoff; Lisette A H M Cornelissen; Gerrit Jan Weverling; Robert H E Friesen; Jaap Goudsmit
Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
The Journal of infectious diseases 2009;200(12):1870-3.
2008: A B H Bakker; C Python; C J Kissling; P Pandya; W E Marissen; M F Brink; F Lagerwerf; S Worst; E van Corven; Stefan Kostense; K Hartmann; Gerrit Jan Weverling; F Uytdehaag; C Herzog; D J Briggs; C E Rupprecht; R Grimaldi; Jaap Goudsmit
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.
Vaccine 2008;26(47):5922-7.
2008: Katarina Radosević; Ariane Rodriguez; Ratna Mintardjo; Dennis Tax; Karin Lövgren Bengtsson; Catherine Thompson; Maria Zambon; Gerrit Jan Weverling; Fons Uytdehaag; Jaap Goudsmit
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Vaccine 2008;26(29-30):3640-6.
2008: Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David Lanar; Menzo J E Havenga; Katarina Radosevic
Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.
Infection and immunity 2008;76(4):1709-18.
2007: Itzchak Samina; Menzo J E Havenga; Wouter Koudstaal; Yevgeny Khinich; Martin Koldijk; Mertyn Malkinson; Michael Simanov; Shmuel Perl; Linda Gijsbers; Gerrit Jan Weverling; Fons Uytdehaag; Jaap Goudsmit
Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
Vaccine 2007;25(49):8338-45.
2007: Martin Koldijk; Johannes A Bogaards; Stefan Kostense; M de Vocht; Linda Gijsbers; M Ter Haak; C Ophorst; J P J Brakenhoff; Gerrit Jan Weverling; Jean-Yves Guichoux; Fons Uytdehaag; J Lewis; Jaap Goudsmit; Giuseppe Marzio
A sensitive cell-based assay for the detection of residual infectious West Nile virus.
Vaccine 2007;25(39-40):6872-81.
2007: Katarina Radosevic; Catharina W Wieland; Ariane Rodriguez; Gerrit Jan Weverling; Ratna Mintardjo; Gert Gillissen; Ronald Vogels; Yasir A W Skeiky; David Hone; Jerald C Sadoff; Tom van der Poll; Menzo J E Havenga; Jaap Goudsmit
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.
Infection and immunity 2007;75(8):4105-15.
2007: V Ann Stewart; Shannon M McGrath; Patrice M Dubois; Maria G Pau; Pascal Mettens; Joseph Shott; Michelle Cobb; J Robert Burge; David Larson; Lisa A Ware; Marie-Ange Demoitie; Gerrit Jan Weverling; Babak Bayat; Jerome H H V Custers; Marie-Claude Dubois; Joe Cohen; Jaap Goudsmit; Donald Heppner
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
Infection and immunity 2007;75(5):2283-90.
2007: Giuseppe Marzio; E Kerkvliet; Johannes A Bogaards; S Koelewijn; A De Groot; Linda Gijsbers; Gerrit Jan Weverling; Ronald Vogels; Menzo J E Havenga; Jerome H H V Custers; MG Pau; Jean-Yves Guichoux; J Lewis; Jaap Goudsmit
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.
Vaccine 2007;25(12):2228-37.
2006: Anna R Thorner; Ronald Vogels; Jorn Kaspers; Gerrit Jan Weverling; Lennart Holterman; Angelique A C Lemckert; Athmanundh Dilraj; lisa mcnally; Prakash Jeena; Soren Jepsen; peter abbink; Anjali Nanda; Patricia E Swanson; Andrew T Bates; Kara L O'Brien; Menzo J E Havenga; Jaap Goudsmit; Dan H Barouch
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
Journal of clinical microbiology 2006;44(10):3781-3.
2006: Johan C Kapteyn; Mohammed Drissi Saidi; René Dijkstra; Cennet Kars; Joan C M S-K Tjon; Gerrit Jan Weverling; Marcel L de Vocht; Ronald Kompier; Bart A van Montfort; Jean-Yves Guichoux; Jaap Goudsmit; Fija Lagerwerf
Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method.
Vaccine 2006;24(16):3137-44.
2006: Sandra Verhaagh; Esmeralda de Jong; Jaap Goudsmit; Sylvie Lecollinet; Gert Gillissen; Margreet de Vries; Kees van Leuven; Ivo Que; Krista Ouwehand; Ratna Mintardjo; Gerrit Jan Weverling; Katarina Radosevic; Jennifer Richardson; Marc Eloit; Clemens Lowik; Paul H A Quax; Menzo J E Havenga
Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors.
The Journal of general virology 2006;87(Pt 2):255-65.
2006: Johannes A Bogaards; Gerrit Jan Weverling; Aeilko H Zwinderman; Patrick Bossuyt; Jaap Goudsmit
Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding.
Journal of acquired immune deficiency syndromes (1999) 2006;41(2):232-7.
2006: Maarten H Biezeveld; Judy Geissler; Gerrit Jan Weverling; Irene M Kuipers; Jan Lam; Jaap Ottenkamp; Taco W Kuijpers
Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease.
Arthritis and rheumatism 2006;54(1):369-76.
2005: Miriam Casula; Gerrit Jan Weverling; Ferdinand W N M Wit; Eveline C Timmermans; Michael Stek; Joep M A Lange; Peter Reiss
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
The Journal of infectious diseases 2005;192(10):1794-800.
2005: Valériane Leroy; charlotte sakarovitch; Mario Cortina Borja; James McIntyre; Hoosen Coovadia; François Dabis; Marie-Louise Newell; J Saba; Glenda Gray; Ch Ndugwa; Ch Kilewo; Augustine Massawe; Praxedes Kituuka; Pius Okong; A Grulich; H von Briesen; J Goudsmit; Gunnel Biberfeld; Geert Haverkamp; Gerrit Jan Weverling; Joep M A Lange
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?
AIDS (London, England) 2005;19(16):1865-75.
2005: Djuna L Cahen; Erik A J Rauws; Paul Fockens; Gerrit Jan Weverling; Kees Huibregtse; M Bruno
Endoscopic drainage of pancreatic pseudocysts: long-term outcome and procedural factors associated with safe and successful treatment.
Endoscopy 2005;37(10):977-83.
2005: Daniel C Aronson; J Marco Schnater; Chris R. Staalman; Gerrit Jan Weverling; Jack Plaschkes; Giorgio Perilongo; Julia Brown; Angela Phillips; Jean-Bernard Otte; Piotr Czauderna; Gordon MacKinlay; Anton Vos
Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1245-52.
2005: Djuna L Cahen; Anne-Marie van Berkel; Daphne Oskam; Erik A J Rauws; Gerrit Jan Weverling; Kees Huibregtse; Marco J Bruno
Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis.
European journal of gastroenterology & hepatology 2005;17(1):103-8.
2005: Regje M E Blümer; Huynh van Thien; An F C Ruiter; Gerrit Jan Weverling; Dang vinh Thuan; Erik Endert; Piet A Kager; Hans P Sauerwein
Adiponectin and glucose production in patients infected with Plasmodium falciparum.
Metabolism: clinical and experimental 2005;54(1):60-6.
2004: Huynh van Thien; Gerrit Jan Weverling; Mariëtte T Ackermans; Nguyen canh Hung; Erik Endert; Piet A Kager; Hans P Sauerwein
FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria.
American journal of physiology. Endocrinology and metabolism 2004;287(4):E609-15.
2004: Gideon Allick; Fleur Sprangers; Gerrit Jan Weverling; Mariëtte T Ackermans; Alfred J Meijer; Johannes A Romijn; Erik Endert; Peter H Bisschop; Hans P Sauerwein
Free fatty acids increase hepatic glycogen content in obese males.
Metabolism: clinical and experimental 2004;53(7):886-93.
2004: Marc van der Valk; Gideon Allick; Gerrit Jan Weverling; Johannes A Romijn; Mariëtte T Ackermans; Joep M A Lange; Berthe L F van Eck-Smit; Cornelis van Kuijk; Erik Endert; Hans P Sauerwein; Peter Reiss
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.
The Journal of clinical endocrinology and metabolism 2004;89(7):3554-60.
2004: Jan ter Meulen; Alexander B H Bakker; Edward N van den Brink; Gerrit Jan Weverling; Byron Martina; Bart L Haagmans; Thijs Kuiken; John de Kruif; Wolfgang Preiser; Willy Spaan; Hans R Gelderblom; Jaap Goudsmit; Albert D M E Osterhaus
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.
Lancet 2004;363(9427):2139-41.
2004: Stefan Kostense; Wouter Koudstaal; Mieke Sprangers; Gerrit Jan Weverling; Germaine Penders; Niels Helmus; Ronald Vogels; Margreet Bakker; Ben Berkhout; Menzo J E Havenga; Jaap Goudsmit
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
AIDS (London, England) 2004;18(8):1213-6.
2004: Antoinette C van der Kuyl; Abeltje M Polstra; Gerrit Jan Weverling; Fokla Zorgdrager; Remco van den Burg; Marion Cornelissen
An IL-8 gene promoter polymorphism is associated with the risk of the development of AIDS-related Kaposi's sarcoma: a case-control study.
AIDS (London, England) 2004;18(8):1206-8.
2004: Huynh van Thien; Mariëtte T Ackermans; Gerrit Jan Weverling; T Dang Vinh; Erik Endert; Piet A Kager; Hans P Sauerwein
Gluconeogenesis and fasting in cerebral malaria.
The Netherlands journal of medicine 2004;62(4):129-33.
2004: Marcus Schultz; Julian L Millo; Marcel Levi; C E Hack; Gerrit Jan Weverling; Christopher S Garrard; Tom van der Poll
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.
Thorax 2004;59(2):130-5.
2004: Huynh van Thien; Mariëtte T Ackermans; Gerrit Jan Weverling; V O Thanh Chien; Erik Endert; Piet A Kager; Hans P Sauerwein
Influence of prolonged starvation on glucose kinetics in pregnant patients infected with Plasmodium falciparum.
Clinical nutrition (Edinburgh, Scotland) 2004;23(1):59-67.
2004: Jesse de Metz; Johannes A Romijn; Erik Endert; Mariëtte T Ackermans; Gerrit Jan Weverling; Olivier R C Busch; Laurence Th de Wit; Dirk J Gouma; Ineke J M ten Berge; Hans P Sauerwein
Interferon-gamma increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients.
Journal of applied physiology (Bethesda, Md. : 1985) 2004;96(2):597-603.
2004: Peter Reiss; Miriam Casula; Anthony de Ronde; Gerrit Jan Weverling; Jaap Goudsmit; Joep M A Lange
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
HIV medicine 2004;5(1):11-4.
2004: Julian L Millo; Marcus Schultz; Conrad Williams; Gerrit Jan Weverling; Timothy Ringrose; Carolyn I Mackinlay; Tom van der Poll; Christopher S Garrard
Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia.
Intensive care medicine 2004;30(1):68-74.
2003: Sanjay U C Sankatsing; Gerrit Jan Weverling; Monika Peeters; Gerben van't Klooster; Boris Gruzdev; Aza Rakhmanova; Sven A Danner; Suzanne Jurriaans; Jan M Prins; Joep M A Lange
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
AIDS (London, England) 2003;17(18):2623-7.
2003: Marijn van Ballegooijen; Johannes A Bogaards; Gerrit Jan Weverling; Maarten C Boerlijst; Jaap Goudsmit
AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):214-20.
2003: Ahmadou Alioum; Mario Cortina Borja; François Dabis; Laurence Dequae-Merchadou; Geert Haverkamp; James Hughes; John M Karon; Valériane Leroy; Marie-Louise Newell; Barbra A Richardson; Liesbeth van Weert; Gerrit Jan Weverling
Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods.
American journal of epidemiology 2003;158(6):596-605.
2003: Anne A M W Van Kempen; Johannes A Romijn; An F C Ruiter; Erik Endert; Gerrit Jan Weverling; Joke H Kok; Hans P Sauerwein
Alanine administration does not stimulate gluconeogenesis in preterm infants.
Metabolism: clinical and experimental 2003;52(8):945-9.
2003: Johannes A Bogaards; Gerrit Jan Weverling; Ronald B Geskus; Frank Miedema; Joep M A Lange; Patrick Bossuyt; Jaap Goudsmit
Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Antiviral therapy 2003;8(1):43-50.
2002: Ferdinand W N M Wit; Ronald P van Rij; Gerrit Jan Weverling; Joep M A Lange; Hanneke Schuitemaker
CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
The Journal of infectious diseases 2002;186(12):1726-32.
2002: Kamilla D Lettinga; Annelies Verbon; Gerrit Jan Weverling; J F P Schellekens; Jeroen W Den Boer; Ed P F Yzerman; Jacobus Prins; Wim G Boersma; Ruud J Van Ketel; Jan M Prins; Peter Speelman
Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy.
Emerging infectious diseases 2002;8(12):1448-54.
2002: Jeanne P Dieleman; Miriam C J M Sturkenboom; Marielle Jambroes; Inge C Gyssens; Gerrit Jan Weverling; Jacob H Ten Veen; Gerrit Schrey; Peter Reiss; Bruno H Ch Stricker
Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort.
Archives of internal medicine 2002;162(13):1493-501.
2002: Neil Renwick; Gerrit Jan Weverling; Joke Brouwer; Margreet Bakker; Thomas F Schulz; Jaap Goudsmit
Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma.
AIDS research and human retroviruses 2002;18(10):695-8.
2002: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan F L Weel; Suzanne Jurriaans; Joep M A Lange
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
The Journal of infectious diseases 2002;186(1):23-31.
2002: Neil Renwick; Nicole Dukers; Gerrit Jan Weverling; Julie Sheldon; Thomas F Schulz; Maria Prins; Roel A Coutinho; Jaap Goudsmit
Risk factors for human herpesvirus 8 infection in a cohort of drug users in the Netherlands, 1985-1996.
The Journal of infectious diseases 2002;185(12):1808-12.
2002: Kiat Ruxrungtham; Sasiwimol Ubolyam; Elly A M Hassink; Chaiwat Ungsedhapand; Eugene D M B Kroon; Chris Duncombe; Gerrit Jan Weverling; Somboon Nookai; Joep Lange; David Cooper; Praphan Phanuphak
Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy.
Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand 2002;20(2):105-11.
2002: Cyriel Y Ponsioen; Jacqueline Defoer; Fiebo J W Ten Kate; Gerrit Jan Weverling; G N J Tytgat; Yvonne Pannekoek; Pauline M E Wertheim-Dillen
A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved?
European journal of gastroenterology & hepatology 2002;14(6):641-8.
2002: Jaap Goudsmit; Johannes A Bogaards; Suzanne Jurriaans; Hanneke Schuitemaker; Joep M A Lange; Roel A Coutinho; Gerrit Jan Weverling
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.
AIDS (London, England) 2002;16(5):791-3.
2002: Jeanne P Dieleman; Marielle Jambroes; Inge C Gyssens; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Wilhelmina M C Mulder; Frank de Wolf; Gerrit Jan Weverling; Joep M A Lange; Peter Reiss; Kees Brinkman
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
AIDS (London, England) 2002;16(5):737-45.
2001: Ahmadou Alioum; François Dabis; Laurence Dequae-Merchadou; Geert Haverkamp; Michael G Hudgens; J Hughes; John M Karon; Valériane Leroy; Marie-Louise Newell; B Richardson; Gerrit Jan Weverling
Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology.
Statistics in medicine 2001;20(23):3539-56.
2001: Jaap Goudsmit; Gerrit Jan Weverling; Lia van der Hoek; Anthony de Ronde; Frank Miedema; Roel A Coutinho; Joep M A Lange; Maarten C Boerlijst
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
AIDS (London, England) 2001;15(17):2293-301.
2001: Neil Renwick; Gerrit Jan Weverling; T Halaby; Peter Portegies; Margreet Bakker; Thomas F Schulz; Jaap Goudsmit
Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex.
AIDS (London, England) 2001;15(16):2165-9.
2001: Marielle Jambroes; Gerrit Jan Weverling; Peter Reiss; Sven A Danner; Suzanne Jurriaans; Jacob H Ten Veen; Marchina E Van Der Ende; Martin Schutten; M M E Schneider; R Schuurman; Jan W Mulder; A C Kroes; Joep M A Lange; Frank de Wolf
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Nederlands tijdschrift voor geneeskunde 2001;145(33):1591-7.
2001: Agnes I Veldkamp; Gerrit Jan Weverling; Joep M A Lange; J S Montaner; Peter Reiss; D A Cooper; STEFANO VELLA; D Hall; Jos H Beijnen; Richard Hoetelmans
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Marc van der Valk; EH Gisolf; Peter Reiss; Ferdinand W N M Wit; A Japour; Gerrit Jan Weverling; Sven A Danner
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
AIDS (London, England) 2001;15(7):847-55.
2001: Neil Renwick; Gerrit Jan Weverling; T Schulz; Jaap Goudsmit
Timing of human immunodeficiency virus type 1 and human herpesvirus 8 infections and length of the Kaposi's sarcoma-free period in coinfected persons.
The Journal of infectious diseases 2001;183(9):1427.
2001: NA Foudraine; Suzanne Jurriaans; Gerrit Jan Weverling; David Burger; Richard Hoetelmans; Marijke Th L Roos; JJ Maas; Frank Miedema; Peter Reiss; Peter Portegies; Frank de Wolf; Joep M A Lange
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Antiviral therapy 2001;6(1):55-62.
2001: Nicole Dukers; Jaap Goudsmit; John B F de Wit; Maria Prins; Gerrit Jan Weverling; Roel A Coutinho
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection.
AIDS (London, England) 2001;15(3):369-78.
2001: MH Reijers; Gerrit Jan Weverling; Suzanne Jurriaans; Marijke Th L Roos; Ferdinand W N M Wit; Hugo M Weigel; Reinier W Ten Kate; Jan W Mulder; Clemens Richter; Hadewych J M ter Hofstede; Herman Sprenger; Richard Hoetelmans; Hanneke Schuitemaker; Joep M A Lange
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
AIDS (London, England) 2001;15(1):129-31.
2000: M den Brinker; Ferdinand W N M Wit; Pauline M E Wertheim-van Dillen; Suzanne Jurriaans; Jan F L Weel; Remko van Leeuwen; Nadine Pakker; Peter Reiss; Sven A Danner; Gerrit Jan Weverling; Joep M A Lange
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
AIDS (London, England) 2000;14(18):2895-902.
2000: EH Gisolf; C Dreezen; Sven A Danner; J L Weel; Gerrit Jan Weverling
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(5):1234-9.
2000: Kiat Ruxrungtham; Eugene D M B Kroon; Chaiwat Ungsedhapand; Somsong Teeratakulpisarn; Sasiwimol Ubolyam; Supranee Buranapraditkun; R van Leeuwen; Gerrit Jan Weverling; Chaiyos Kunanusont; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
AIDS (London, England) 2000;14(10):1375-82.
2000: Rieneke van Praag; Gerrit Jan Weverling; Peter Portegies; Suzanne Jurriaans; X J Zhou; M L Turner-Foisy; Jean-Pierre Sommadossi; David Burger; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS (London, England) 2000;14(9):1187-94.
2000: Jaap Goudsmit; Neil Renwick; Nicole Dukers; Roel A Coutinho; Siem H Heisterkamp; Margreet Bakker; Thomas F Schulz; Marion Cornelissen; Gerrit Jan Weverling
Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(9):4838-43.
2000: Nicole Dukers; Neil Renwick; Maria Prins; Ronald B Geskus; Thomas F Schulz; Gerrit Jan Weverling; Roel A Coutinho; Jaap Goudsmit
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men.
American journal of epidemiology 2000;151(3):213-24.
2000: Brian S N Blank; Pieter L Meenhorst; Jan W Mulder; Gerrit Jan Weverling; H Putter; W Pauw; WC van Dijk; P Smits; S Lie-A-Ling; P Reiss; Joep M A Lange
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.
Journal of clinical microbiology 2000;38(2):563-9.
2000: Roelien H Enting; NA Foudraine; Joep M A Lange; Suzanne Jurriaans; Tom van der Poll; Gerrit Jan Weverling; Peter Portegies
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
Journal of neuroimmunology 2000;102(2):216-21.
2000: MH Reijers; Hugo M Weigel; A A Hart; Reinier W Ten Kate; Jan W Mulder; Peter Reiss; Hanneke Schuitemaker; Richard Hoetelmans; Gerrit Jan Weverling; Joep M A Lange
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
AIDS (London, England) 2000;14(1):59-67.
1999: Brian S N Blank; Pieter L Meenhorst; Gerrit Jan Weverling; A A Stout-Zonneveld; W Pauw; Jan W Mulder; WC van Dijk; P Smits; Joep M A Lange
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients.
AIDS (London, England) 1999;13(18):2533-9.
1999: Gerrit Jan Weverling; Amanda Mocroft; bruno ledergerber; Ole Kirk; J Gonzáles-Lahoz; A d'Arminio Monforte; R Proenca; Andrew N Phillips; Jens D Lundgren; P Reiss
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Lancet 1999;353(9161):1293-8.
1999: Ferdinand W N M Wit; Remko van Leeuwen; Gerrit Jan Weverling; Suzanne Jurriaans; K Nauta; Radjin Steingrover; J Schuijtemaker; X Eyssen; D Fortuin; M Weeda; Frank de Wolf; Peter Reiss; Sven A Danner; Joep M A Lange
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 1999;179(4):790-8.
1998: Neil Renwick; T Halaby; Gerrit Jan Weverling; Nicole Dukers; Guy R Simpson; Roel A Coutinho; Joep M A Lange; Thomas F Schulz; Jaap Goudsmit
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
AIDS (London, England) 1998;12(18):2481-8.
1998: MH Reijers; Gerrit Jan Weverling; Suzanne Jurriaans; Ferdinand W N M Wit; R van Leeuwen; Sylvia M Bruisten; P H J Frissen; Hugo M Weigel; Jan W Mulder; Reinier W Ten Kate; Frank de Wolf; Hanneke Schuitemaker; Joep M A Lange
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Nederlands tijdschrift voor geneeskunde 1998;142(40):2230.
1998: Sylvia M Bruisten; P Reiss; A E Loeliger; P Van Swieten; R Schuurman; C A Boucher; Gerrit Jan Weverling; J G Huisman
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
AIDS research and human retroviruses 1998;14(12):1053-8.
1998: Gerrit Jan Weverling; Joep M A Lange; Suzanne Jurriaans; Jan M Prins; Vladimir V Lukashov; Daan W Notermans; M Roos; Hanneke Schuitemaker; Richard Hoetelmans; Sven A Danner; Jaap Goudsmit; Frank de Wolf
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
AIDS (London, England) 1998;12(11):F117-22.
1998: Richard Hoetelmans; MH Reijers; Gerrit Jan Weverling; Reinier W Ten Kate; Ferdinand W N M Wit; Jan W Mulder; Hugo M Weigel; P H J Frissen; M Roos; Suzanne Jurriaans; Hanneke Schuitemaker; Frank de Wolf; Jos H Beijnen; Joep M A Lange
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: MH Reijers; Gerrit Jan Weverling; S Jurriaans; Ferdinand W N M Wit; Hugo M Weigel; Reinier W Ten Kate; Jan W Mulder; P H J Frissen; R van Leeuwen; P Reiss; H Schuitemaker; Frank de Wolf; Joep M A Lange
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Lancet 1998;352(9123):185-90.
1998: NA Foudraine; Gerrit Jan Weverling; T van Gool; Marijke Th L Roos; Frank de Wolf; Peter P Koopmans; Peterhans J Van den Broek; Pieter L Meenhorst; Remko van Leeuwen; Joep M A Lange; Peter Reiss
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
AIDS (London, England) 1998;12(1):35-41.
1997: E S Louwerse; C E Visser; Patrick Bossuyt; Gerrit Jan Weverling
Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium.
Journal of the neurological sciences 1997;152 Suppl 1():S10-7.
1997: Jan M Prins; Gerrit Jan Weverling; Ruud J Van Ketel; Peter Speelman
Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients.
Clinical pharmacology and therapeutics 1997;62(1):106-11.
1997: Menno D De Jong; STEFANO VELLA; Andrew Carr; Charles A B Boucher; A Imrie; Martyn French; Jennifer Hoy; S Sorice; S Pauluzzi; F Chiodo; Gerrit Jan Weverling; Marchina E Van Der Ende; P J Frissen; Hugo M Weigel; Robbert H Kauffmann; Joep M A Lange; R Yoon; M Moroni; E Hoenderdos; G Leitz; David A Cooper; D Hall; Peter Reiss
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1996: Gerrit Jan Weverling; Joep M A Lange; Menno D De Jong; H de Weerd; J Goudsmit; Frank de Wolf
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.
Antiviral therapy 1996;1(4):255-63.
1996: Rob Schuurman; Diane Descamps; Gerrit Jan Weverling; S Kaye; J Tijnagel; I Williams; R van Leeuwen; R Tedder; Charles A B Boucher; Françoise Brun Vezinet; C Loveday
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.
Journal of clinical microbiology 1996;34(12):3016-22.
1996: Evelien Dekker; Johannes A Romijn; Catherine Waruiru; Mariëtte T Ackermans; Gerrit Jan Weverling; Robert W Sauerwein; Erik Endert; Norbert Peshu; Kevin Marsh; Hans P Sauerwein
The relationship between glucose production and plasma glucose concentration in children with falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1996;90(6):654-7.
1996: J M Prins; Gerrit Jan Weverling; K de Blok; Ruud J Van Ketel; Peter Speelman
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.
Antimicrobial agents and chemotherapy 1996;40(11):2494-9.
1996: P H J Frissen; Gerrit Jan Weverling; Erik Endert; J Jansen; H P Sauerwein; Joep M A Lange
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(5):482-8.
1996: Annelies Verbon; Gerrit Jan Weverling
Acute upper gastrointestinal haemorrhage.
Lancet 1996;348(9021):201.
1995: M H Godfried; Tom van der Poll; Jan W Mulder; Gerrit Jan Weverling; Erik Endert; Joep M A Lange; Hans P Sauerwein
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(5):531-9.
1995: M H Godfried; Johannes A Romijn; Tom van der Poll; Gerrit Jan Weverling; EP Corssmit; Erik Endert; J K Eeftinck Schattenkerk; Hans P Sauerwein
Soluble receptors for tumor necrosis factor are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection.
Metabolism: clinical and experimental 1995;44(12):1564-9.
1995: Nine van der Vange; Gerrit Jan Weverling; B W Ketting; Willem M Ankum; RA Samlal; FB Lammes
The prognosis of cervical cancer associated with pregnancy: a matched cohort study.
Obstetrics and gynecology 1995;85(6):1022-6.
1995: E S Louwerse; Gerrit Jan Weverling; Patrick Bossuyt; F E Meyjes; J M de Jong
Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.
Archives of neurology 1995;52(6):559-64.
1995: Patrick Bossuyt; E S Louwerse; Gerrit Jan Weverling; J M de Jong
Baseline assessments in amyotrophic lateral sclerosis trials.
Journal of the neurological sciences 1995;129 Suppl():28.
1995: E S Louwerse; Patrick Bossuyt; Gerrit Jan Weverling; J M de Jong
Mortality risk stratification in amyotrophic lateral sclerosis.
Journal of the neurological sciences 1995;129 Suppl():27.
1995: Suzanne Jurriaans; Gerrit Jan Weverling; Jaap Goudsmit; J Boogaard; M Brok; D Van Strijp; J Lange; M Koot; B Van Gemen
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
AIDS research and human retroviruses 1995;11(4):473-9.
1994: Bjorn M Van Geel; Johanna Assies; Gerrit Jan Weverling; Peter G Barth
Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindreds.
Neurology 1994;44(12):2343-6.
1994: Suzanne Jurriaans; B Van Gemen; Gerrit Jan Weverling; D Van Strijp; P Nara; Roel A Coutinho; M Koot; Hanneke Schuitemaker; Jaap Goudsmit
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
Virology 1994;204(1):223-33.
1994: P H J Frissen; Marchina E Van Der Ende; C H ten Napel; Hugo M Weigel; G S Schreij; Robbert H Kauffmann; Peter P Koopmans; A I Hoepelman; J B de Boer; Gerrit Jan Weverling
Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1994;169(6):1351-5.
1994: M H Godfried; Tom van der Poll; Gerrit Jan Weverling; Jan W Mulder; J Jansen; Sander J H van Deventer; Hans P Sauerwein
Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1994;169(4):739-45.
1993: Annelies Verbon; Gerrit Jan Weverling; Sjoukje Kuijper; Peter Speelman; Henk M Jansen; Arend H J Kolk
Evaluation of different tests for the serodiagnosis of tuberculosis and the use of likelihood ratios in serology.
The American review of respiratory disease 1993;148(2):378-84.
1992: Charles A B Boucher; Joep M A Lange; Frank Miedema; Gerrit Jan Weverling; M Koot; Jan W Mulder; Jaap Goudsmit; Kellam Paul; Brendan Larder; M Tersmette
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
AIDS (London, England) 1992;6(11):1259-64.